Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
34 authors.
Dorothy Hallberg *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-7952-0622
Alice C Eastman *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0103-0055
Shashikant Koul *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9690-7349
Daniel C BruhmThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8436-501X
Eniko PappThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9022-7238
Simon DavenportDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0002-4860-7472
Vilmos AdleffThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5001-1766
Leonardo FerreiraThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-2468-2689
Noushin NiknafsThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4852-3674
Jamie E MedinaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6124-0548
Stephen CristianoThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7375-2364
Carolyn HrubanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9882-040X
Jacob FikselThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-7067-1334
Kaui P LebarbenchonThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7096-6308
Luis AparicioThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8016-0455
Nicholas A VulpescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1310-0257
Kuan-Ting KuoDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-3657-1652
Nita AhujaThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8293-1893
Ronny DrapkinDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-6912-6977
Euihye JungDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-1202-247X
Sarah H KimDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-1381-6781
Mark A EckertDepartment of Obstetrics and Gynecology and Section of Gynecologic Oncology, The University of Chicago, Chicago, Illinois.ORCID 0000-0003-3166-3440
Ernst LengyelDepartment of Obstetrics and Gynecology and Section of Gynecologic Oncology, The University of Chicago, Chicago, Illinois.ORCID 0000-0001-8624-1507
Kentaro NakayamaDepartment of Gynecology and Obstetrics, Nagoya City University East Medical Center, Nagoya, Japan.ORCID 0000-0002-3250-3097
Ayse AyhanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0136-4271
Ie-Ming ShihThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1084-2071
Tian-Li WangDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0002-7082-449X
Ofer LavieDivision of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.ORCID 0000-0003-0809-3777
Gad RennertB. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and The Association for Promotion of Research in Precision Medicine, Haifa, Israel.ORCID 0000-0002-8512-068X
Hariharan EaswaranThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5517-2972
Stephen B BaylinThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3697-3798
Michael F PressDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0003-3400-6614
Victor E VelculescuThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1195-438X
Robert B ScharpfThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4702-2656
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
Vaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1M
SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ronny I DRAPKIN, IE-MING SHIH · 2018 to 2026
$20.5M
Large-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3M
DNA evaluation of fragments for early interception (DELFI) of Lung cancerU01CA271896 · NCI · JOHNS HOPKINS UNIVERSITY · PI DAVID SIDRANSKY, Victor E. Velculescu · 2023 to 2026
$3.8M
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancerU01CA200469 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING, ZHANG, ZHEN · 2016 to 2021
$2.9M
Predoctoral Training Program in Human GeneticsT32GM148383 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Kimberly F Doheny, ANDREW S MCCALLION · 2023 to 2026
$2.4M
Commonwealth Foundation for Cancer Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)Gray FoundationHonorable Tina Brozman Foundation (Tina's Wish)National Institute of General Medical Sciences (NIGMS) T32GM148383National Institutes of Health (NIH) CA006973National Institutes of Health (NIH) CA062924National Institutes of Health (NIH) CA083636National Institutes of Health (NIH) CA121113National Institutes of Health (NIH) CA200469National Institutes of Health (NIH) CA228991National Institutes of Health (NIH) CA271896NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA083636NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA121113NCI NIH HHS U01 CA200469NCI NIH HHS U01 CA271896NIGMS NIH HHS T32 GM148383Stand Up To Cancer (SU2C) SU2C-AACR-DT1415U.S. Department of Defense (DOD) OCRP-OC-100517
6 · The paper itself
Abstract
Endometrioid and mucinous ovarian carcinomas represent nearly a fifth of ovarian cancers, but their molecular characteristics and pathologic origins are poorly understood. To identify the genomic and epigenomic alterations characteristic of these ovarian cancer subtypes and evaluate links to morphologically similar tumors from other sites, we performed a combination of sequence, copy number, mutation signature, and rearrangement analyses from tumor samples and matched normal tissues of 133 patients, as well as methylation analyses of these tumors and tissues of 150 patients from The Cancer Genome Atlas. Genomic analyses included samples from patients with ovarian endometrioid (n = 44), ovarian mucinous (n = 43), uterine endometrioid (n = 15), and gastrointestinal mucinous carcinomas (n = 31), including mucinous carcinomas of the stomach, colon, and pancreas. In addition to identifying genes previously known to be involved in these tumors, we identified alterations in RAD51C, NOTCH4, SMARCA1/4, and JAK1 in ovarian endometrioid, ESR1 in uterine endometrioid, and SMARCA4 in ovarian mucinous carcinomas. Whole-genome sequencing revealed rearrangements involving PTEN, NF1, and NF2 in ovarian endometrioid carcinomas and NF1 and MED1 in ovarian mucinous carcinomas. The number of alterations, affected genes, and genome-wide methylation profiles were not distinguishable between ovarian and uterine endometrioid carcinomas, supporting the hypothesis that these tumors share a tissue of origin. In contrast, mutation and methylation patterns in ovarian mucinous carcinomas were different from gastrointestinal mucinous carcinomas. These analyses provide insights into the genomic landscapes and origins of mucinous and endometrioid ovarian carcinomas, providing new avenues for early clinical intervention and management of patients with these cancers. SIGNIFICANCE: Integrative multi-omic analyses support a common tissue of origin between ovarian endometrioid and uterine endometrioid carcinomas but not between ovarian mucinous and gastric or pancreatic mucinous carcinomas.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types. · full record | OpenQuestion